Biomea Fusion, Inc. (BMEA) closed the last trading session at $5.71, gaining 2% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $23.86 indicates a 317.9% upside potential.The mean estimate comprises seven short-term price targets with a standard deviation of $20.63. While the lowest estimate of $5 indicates a 12.4% decline from the current price level, the most optimistic analyst e ...

REDWOOD CITY, Calif., June 03, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA) ("Biomea" or the "Company"), a clinical stage biopharmaceutical company focused on the discovery and development of covalent small molecules to treat patients with genetically defined cancers and metabolic diseases, today announced that on June 1, 2024, the compensation committee of Biomea's board of directors granted one new employee non-qualified stock options to purchase an aggregate of 25,000 shares of the Company ...

产品管线 - 公司正在开发两款临床候选药物BMF-219和BMF-500[59] - BMF-219是一种口服可用的、强效且选择性的covalent抑制剂,可抑制menin蛋白,用于治疗糖尿病和某些癌症[60] - BMF-219在2型糖尿病和1型糖尿病的临床试验中显示出改善胰岛β细胞功能和再生的潜力[62,63,64,65,66,67,68] - BMF-219在血液肿瘤和实体瘤的临床试验中也显示出初步疗效,包括在复发/难治性急性髓系白血病中观察到完全缓解[70,72,73] - BMF-500是一种针对FLT3突变的第三代口服covalent小分子抑制剂,正在开展I期临床试验[76] 财务状况 - 公司自2017年成立以来一直专注于研发活动,尚未产生任何产品销售收入,预计未来会持续亏损并需要筹集更多资金[75,76] - 公司目前依赖并预计将继续依赖第三方制造其产品候选药物[77] - 公司尚未产生任何收入且在短期内不预期从产品销售中产生任何收入[78] - 研发费用将在未来几年内大幅增加,以推进临床试验、获得监管批准并推进其他项目[79][80] - 研发费用增加主要由于临床活动相关费用增加11.8百万美元[85][86] - 一般及行政费用增加主要由于人员相关费用增加2.1百万美元[87] - 公司目前的现金、现金等价物和受限现金不足以支持其运营费用和资本支出需求至少12个月,存在持续经营的重大不确定性[88] - 公司将继续需要额外资本来开发产品候选药物并为可预见的未来提供运营资金[89] - 公司可能寻求通过公开或私募股权发行、债务融资、合作和许可安排或其他渠道筹集资金[89] - 如果公司无法按需筹集资本,可能会对其财务状况和业务策略的执行能力产生负面影响[89] - 公司预计将需要筹集大量额外资本,其金额需求取决于多个因素[89] - 公司持有1.137亿美元的现金、现金等价物和受限现金[99] - 公司没有重大外汇风险,利率波动对现金等价物的公允价值影响也不大[99]

临床试验进展 - 公司正在与FDA合作解决BMF-219在2型和1型糖尿病临床试验的临时停止问题[5] - BMF-219在1型糖尿病患者中初步显示了临床活性,改善了胰岛素分泌功能,且耐受性良好[5] - COVALENT-111 2b期临床试验(约195例患者)预计于2024年第四季度完成[5] - COVALENT-112 2a期临床试验(约20例患者)预计于2024年第四季度完成[5] - 公司预计在2024年底前完成COVALENT-101、COVALENT-102和COVALENT-103的剂量递增部分[5] 新项目开发 - 公司计划于2024年第三季度宣布第三个研发项目,一种口服、选择性的GLP-1受体激动剂[5] - 公司正在继续开发FUSION™平台技术[6] 财务情况 - 公司现金、现金等价物和受限现金为1.137亿美元,较2023年12月31日的1.772亿美元有所下降[7] - 研发费用增加主要是由于临床和临前研发成本的增加,以及人员成本的上升[7] - 一般及管理费用增加主要是由于人员相关费用(包括股份支付)和外部顾问及法律费用的增加[7]

COVALENT-111 Phase 2b on track for Q4 2024 readout COVALENT-112 Phase 2a on track for Q4 2024 readout Announcement of the third program in obesity on track for Q3 2024 REDWOOD CITY, Calif., July 31, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. ("Biomea" or "the Company") (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing oral covalent small molecules to treat and improve the lives of patients with metabolic diseases and genetically defined cancers, reported se ...

COVALENT-111 Phase 2b on track for Q4 2024 readoutCOVALENT-112 Phase 2a on track for Q4 2024 readoutAnnouncement of the third program in obesity on track for Q3 2024 REDWOOD CITY, Calif., July 31, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “the Company”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing oral covalent small molecules to treat and improve the lives of patients with metabolic diseases and genetically defined cancers, reported seco ...

NEW YORK, July 08, 2024 (GLOBE NEWSWIRE) -- Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Biomea Fusion, Inc. (NASDAQ: BMEA) resulting from allegations that Biomea Fusion may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Biomea Fusion securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee ...

NEW YORK, June 24, 2024 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Biomea Fusion, Inc. (NASDAQ: BMEA) resulting from allegations that Biomea Fusion may have issued materially misleading business information to the investing public. So what: If you purchased Biomea Fusion securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arran ...

NEW YORK, June 20, 2024 (GLOBE NEWSWIRE) -- Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Biomea Fusion, Inc. (NASDAQ: BMEA) resulting from allegations that Biomea Fusion may have issued materially misleading business information to the investing public. So what: If you purchased Biomea Fusion securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency ...

NEW YORK, June 16, 2024 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Biomea Fusion, Inc. (NASDAQ: BMEA) resulting from allegations that Biomea Fusion may have issued materially misleading business information to the investing public. So what: If you purchased Biomea Fusion securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee a ...